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CD1d-restricted natural killer T cells (NKT cells)
possess awide rangeof effector and regulatory activ-
ities that are related to their ability to secrete both
T helper 1 (Th1) cell- and Th2 cell-type cytokines.
WeanalyzedpresentationofNKTcell activatingagal-
actosylceramide (aGalCer) analogs thatgivepredom-
inantly Th2 cell-type cytokine responses to determine
how ligand structure controls theoutcomeofNKTcell
activation. Using a monoclonal antibody specific for
aGalCer-CD1d complexes to visualize and quantitate
glycolipid presentation, we found that Th2 cell-type
cytokine-biasing ligands were characterized by rapid
and direct loading of cell-surface CD1d proteins.
Complexes formed by association of these Th2 cell-
type cytokine-biasing aGalCer analogs with CD1d
showed a distinctive exclusion from ganglioside-en-
riched, detergent-resistant plasmamembranemicro-
domains of antigen-presenting cells. These findings
help to explain how subtle alterations in glycolipid
ligand structure can control the balance of proinflam-
matory and anti-inflammatory activities of NKT cells.
INTRODUCTION
Natural killer T cells (NKT cells) comprise several unconventional
T cell subsets that coexpress T cell antigen receptors (TCRs) and
various receptors that are prominently expressed by NK cells
(Godfrey et al., 2004). Among the several subsets of NKT cells,
the most well studied are those that express an invariant TCRa
chain, which are known as type 1 or invariant NKT cells (iNKT
cells). These recognize glycolipid antigens presented by the non-
polymorphic MHC class I-like molecule CD1d (Bendelac et al.,
2007). Upon activation, iNKT cells release IFN-g and other proin-888 Immunity 30, 888–898, June 19, 2009 ª2009 Elsevier Inc.flammatory cytokines, aswell as activate a variety of other leuko-
cytes to express effector functions. Through a combination of
these and other activities, iNKT cells can exert major effects on
early and delayed adaptive immunity to tumors and to a wide
variety of infectious pathogens (Crowe et al., 2005; Behar and
Porcelli, 2007). In addition, iNKT cells also contribute to mainte-
nance of immune tolerance (Yu and Porcelli, 2005; Jiang et al.,
2007). This is believed to be related at least in part to the innate
programming of iNKT cells to produce a variety of anti-inflamma-
tory or regulatory cytokines, including high amounts of several
T helper 2 (Th2) cell-associated cytokines such as IL-4, IL-5,
and IL-13 (Im et al., 2006; Sakuishi et al., 2007).
A major advance in iNKT cell research was the discovery of
specific glycolipid ligands that are recognized by these cells
when presented by CD1d. The prototypical iNKT cell activator
is a synthetic form of a-galactosylceramide with a C18 phytos-
phingosine base and a fully saturated C26 N-linked fatty acyl
chain, here referred to as aGalCer-C26:0 (Kawano et al., 1997).
Many studies have shown that aGalCer-C26:0 is a potent acti-
vator of both mouse and human iNKT cells and that it elicits
production of both Th1 cell- and Th2 cell-type cytokines. There
has been substantial effort toward identifying activating ligands
that can more precisely focus the outcome of the iNKT cell
response, and several studies have shown that alterations of
the basic lipid structure of aGalCer-C26:0 can lead to striking
changes in the patterns of cytokine production (Miyamoto
et al., 2001; Schmieg et al., 2003; Goff et al., 2004; Yu et al.,
2005; Fujio et al., 2006). The ability of an iNKT cell-activating
ligand to induce a bias toward production of cytokines associ-
ated with Th2 cell responses was first described for the aGalCer
analog designated OCH, in which the sphingoid base was trun-
cated to C9 and the fatty acid chain was slightly shortened to
C24:0 (Miyamoto et al., 2001). A similar cytokine-biasing prop-
erty was described by our studies of an aGalCer derivative con-
taining an 11,14-cis-diunsaturated C20 fatty acid (aGalCer
C20:2) (Yu et al., 2005) and by another study of aGalCer analogs
with truncated fatty acyl chains (Goff et al., 2004). Conversely,
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(A) Structures and nomenclature of iNKT cell-acti-
vating aGalCer analogs used in this study. The
nomenclature used in most cases is based on
the identity of the amide-linked acyl group in the
ceramide moiety. Acyl carbon chain length and
number of unsaturations are indicated by the
names of most analogs, with exceptions being
OCH (which has a C24 saturated acyl chain) and
the compounds with amide-linked prostaglandin
B1 (PGB1) or 4-fluorophenyl acetate (4FPA)
groups. The phytosphingosine base is 18 carbons
in length for all analogs except OCH, which has
a nine-carbon base.
(B) Hybridoma DN3A4.1-2 (Vb8.2+) was stimulated
with each of the aGalCer analogs at a range of
concentrations with JAWS II cells as APCs, and
the amounts of IL-2 production were analyzed.
Potencies of glycolipids are shown as 1/EC50 (as
defined in Figure S1). The graph shows mean
values ± SD, and the results shown are represen-
tative of three independent experiments.
(C)Ratiosof IL-4 to IFN-g (x axis) plottedagainst the
ratios of IL-13 to IFN-g (y axis) for culture superna-
tants of BALB/c splenocytes stimulatedwith glyco-
lipids for 48 hr. Ratios for the C26:0 and C24:0
analogs are shown for stimulation with a range of
glycolipid concentrations (3, 10, and 30 nM). Other
analogs are shown at one concentration (3 nM) for
clarity, although similar trends were observed at
higher glycolipid concentrations (Figure S2). Data
are representative of three experiments.
(D) C57BL/6 mice (four mice per group) received
a single injection i.p. of four nanomoles of each
glycolipid, and blood samples were obtained at 2,
8, and 23 hr. Concentrations of IFN-g, IL-4, and
IL-12p70 were determined in serum by capture
ELISA. ‘‘ND’’ stands for not detected. The graphs
show mean ± SD for triplicate values, and results
shown were representative of two independent
experiments.a few derivatives of aGalCer have been described that polarize
the cytokine response in the opposite direction, with IFN-g pre-
dominating over IL-4 production (Schmieg et al., 2003; Fujio
et al., 2006; Chang et al., 2007). These compounds are of interest
as selective activators of iNKT cell functions, and such activators
may lend themselves to a variety of therapeutic applications
(Miyake and Yamamura, 2005). However, the mechanisms by
which structural variants of aGalCer induce selective activation
of iNKT cell functions are not clearly understood, and this
imposes limits on rational development of optimized iNKT cell
activators for specific applications.
In the current study,weused apanel of analogs ofaGalCer that
induced preferential production of Th2 cell-type cytokines to
explore themechanismbywhich these compounds induce these
biased cytokine responses. Although these aGalCer analogs
showed marked variability in their avidities for the TCRs of iNKT
cells, they consistently displayed the ability to rapidly load onto
CD1dmolecules directly at the cell surface of antigen-presenting
cells (APCs). This rapid loading of CD1d could be directly visual-
ized with a recently developed monoclonal antibody specific for
the complex formed by the binding of aGalCer to murine CD1d.
Most notably, aGalCer-CD1d complexes containing Th2 cell-type cytokine-biasing analogs showed a marked depletion in
their localization to ganglioside-enriched, detergent-resistant
microdomains in the plasma membranes of APCs, providing a
mechanistic link between the structure of CD1d-binding glyco-
lipids and their ability to preferentially induce immunoregulatory
activities of iNKT cells.
RESULTS
Th2 Cell-Type Cytokine-Biasing aGalCer Analogs
for Murine iNKT Cells
Eight synthetic aGalCer analogs (Figure 1A) were selected for
use in this study from two synthetic libraries of N-acyl variants
of the basic a-galactosyl C18 phytosphingosine structure (Yu
et al., 2005; Li et al., 2007). Among these were two compounds
that induce mixed Th1 and Th2 cell-type cytokine responses,
aGalCer-26:0 and the closely related aGalCer-C24:0 variant
(Forestier et al., 2007). The six analogs that induced predomi-
nantly Th2 cell-type cytokine responses included the previously
described OCH and aGalCer-C20:2 and -C20:4 compounds
(Miyamoto et al., 2001; Yu et al., 2005) and three additional
N-acyl derivatives of the a-galactosyl C18 phytosphingosineImmunity 30, 888–898, June 19, 2009 ª2009 Elsevier Inc. 889
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Interactions with aGalCer Analogs
(A) Flow cytometry analysis of human and murine
iNKT cells with aGalCer analog-CD1d tetramers.
In the top row, murine iNKT cells from C57BL/6
splenocytes were costained with aGalCer analog-
loaded or unloaded mCD1d tetramers conjugated
with PE (x axis) and aGalCer-C26:0-loaded-
mCD1d tetramers conjugated with APC (y axis).
In the bottom row, human PBMCs were similarly
costained with human glycolipid-loaded CD1d
tetramers.
(B)Binding avidity of glycolipid-mCD1dcomplexes
to murine iNKT cell TCRs. Histograms at left show
tetramer stainingofNK1.1+CD3+ T cells inC57BL/6
splenocytes with glycolipid-loaded tetramers at
20 nM.Mean fluorescence intensity (MFI) for stain-
ing of this population with tetramers at various
concentrations is plotted (center), and the equilib-
rium dissociation constants (KD) were determined
as the concentrations of glycolipid-mCD1d com-
plexes required to yield 50% of maximal binding.
Values are plotted as 1/KD, which is directly
proportional to TCR avidity (right).
(C) Similar experiments as in (B) for binding of
aGalCer-hCD1d tetramers to a human iNKT cell
clone (CD4+ clone HDD11). All results shown
were representative of two independent experi-
ments.base. These compoundswere selected because of their ability to
potently activate mouse iNKT cell hybridomas (Figure 1B and
Figure S1 available online), as well as their induction of increased
ratios of IL-13 or IL-4 to IFN-g from mouse splenocytes
(Figure 1C and Figure S2). In vivo analysis revealed that injection
of mice with five of the six Th2 cell-type cytokine-biasing analogs
produced concentrations of circulating IL-4 that were similar to
or greater than those produced by injection of aGalCer-C26:0
and -C24:0 compounds (Figure 1D), but in all cases these
compounds elicited low or undetectable serum IFN-g either early
(2 hr) or late (23 hr) after injection. As we previously reported (For-
estier et al., 2007), circulating IL-12p70 concentrations in vivo did
not correlate with the Th2 cell-type cytokine-biasing properties
of either OCH or aGalCer-C20:2, although other analogs with
a similar bias toward Th2 cell-type cytokine production showed
a tendency toward reduced IL-12p70 production (Figure 1D).
One of the analogs studied, aGalCer-4FPA, showed minimal
activity in vivo in C57BL/6 mice (Figure 1D) but was included
because of its pronounced Th2 cell-type biasing effect in vitro.
Most of the aGalCer analogs in this panel were also able to
strongly stimulate human iNKT cells in vitro (Figure S3).
Murine and Human iNKT Cell TCR Interactions
with aGalCer Analogs
The interactions of iNKT cell TCRs with CD1d molecules loaded
with aGalCer analogs were analyzed with fluorescent murine
and human CD1d tetramers. This demonstrated that iNKT cells
recognizing each analog were also strongly reactive with890 Immunity 30, 888–898, June 19, 2009 ª2009 Elsevier Inc.aGalCer-C26:0, although staining patterns in some cases indi-
cated differences in relative TCR avidities (Figure 2A). Equilib-
rium binding studies for measuring TCR avidities were carried
out by incubation of human or murine iNKT cells with varying
concentrations of aGalCer-analog-loaded tetramers and deter-
mining relative levels of cell-associated fluorescence (Stanic
et al., 2003; Yu et al., 2005). A wide range of TCR avidities was
observed for mouse CD1d (mCD1d) and human CD1d (hCD1d)
complexes formed with different Th2 cell-type cytokine-biasing
aGalCer analogs (Figures 2B and 2C). Notably, complexes
loaded with some of these analogs showed avidities that were
equal to or exceeded those of aGalCer-C26:0 or -C24:0 loaded
complexes, arguing that low TCR avidity was not themain or sole
determinant responsible for altered cytokine responses.
APC Requirement and Kinetic Features of Presentation
of aGalCer Analogs
A previous study suggested that an iNKT cell response biased
toward production of Th2 cell-type cytokines could result from
preferential presentation of aGalCer by B lymphocytes (Bez-
bradica et al., 2005). We studied this possibility directly by using
a monoclonal antibody (L363) that specifically recognizes
complexes of aGalCer bound to mCD1d (Yu et al., 2007). Mouse
splenocytes were cultured with either aGalCer-C26:0 or repre-
sentative Th2 cell-type cytokine-biasing analogs, and L363
staining was assessed on various cell types (Figure 3A). This re-
vealed that all aGalCer analogs were presented most promi-
nently on CD11c+ DCs, and only one of the two analogs that
Immunity
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aGalCer Analogs with Complex-Specific
mAb Staining
(A) Mouse splenocytes cultured with either vehicle
only (0.02% DMSO) or with the indicated aGalCer
analogs (100 nM) were harvested after 1 hr or 19 hr
of incubation and stained with mAb L363 or anti-
CD1d mAb 1B1 and with mAbs specific for
CD11c, CD19, and F4/80 (Figure S4). Filled histo-
grams show L363 staining of cells cultured with
vehicle only, and open histograms show cells
cultured with indicated glycolipids. At the left, the
total CD1d staining with mAb 1B1 (open histo-
grams) compared to isotype control mAb (filled
histograms) are shown on cells cultured for 19 hr
with DMSO only.
(B) JAWS II cells were incubated with glycolipids
(250 nM) for various times ranging from 0.5–18 hr
as indicated, stained with mAb L363, and
analyzed by flow cytometry. Dashed line histo-
grams show L363 staining of cells incubated with
medium only, and bold histograms show L363
staining of cells incubated with aGalCer analogs.
(C) JAWS II cells were pulsed with indicated
aGalCer analogs (500 nM) for 1.5 hr, washed
extensively, and recultured at 37C for various
chase times. Upon harvesting, cells were placed
on ice and subsequently stained with mAb L363
for flow cytometry analysis. Histogram overlays
show L363 staining of cells pulsed initially with
vehicle only (DMSO, dashed histograms) or with
aGalCer analog (bold histograms). The graph on
the right showsMFI of L363 staining at each chase
time represented as percent of the maximum
value measured during the course of the experi-
ment. All results shown (A, B, and C) were repre-
sentative of at least two independent experiments.induced a Th2 cell-type cytokine response showed clearly
detectable presentation by B cells even after prolonged incuba-
tion (19 hr). However, the extremely early appearance of L363
staining on cells exposed to aGalCer-C10:0 suggested that rapid
kinetics of presentation might be a key feature of aGalCer
analogs that induce a bias toward Th2 cell-type cytokines. This
was investigated further with more detailed kinetic studies in
which immortalized mouse DC line JAWS II was cultured with
each glycolipid and assessed for L363 surface staining at 0.5,
4, and 18 hr (Figure 3B). There was a striking correlation between
rapid kinetics of glycolipid association with mCD1d and the
ability to induce a Th2 cell-type cytokine response. For analogs
that induced a mixed cytokine response (aGalCer-C26:0
and -C24:0), strong L363 staining was detected only at 18 hr.
In contrast, most analogs inducing Th2 cell-type cytokine re-
sponses gave strong L363 staining by 0.5 hr, which increased
modestly or not at all with longer incubation. The single excep-
tion was OCH, which in general gave very weak L363 reactivity,
although this was also apparent by 4 hr. A pulse-chase analysis
revealed that mCD1d-aGalCer surface complexes formed
slowly with aGalCer-C26:0 and continued to accumulate
throughout the 8 hr chase (Figure 3C), whereas with aGalCer-
C20:2 or -C10:0, the complexes formed rapidly and began
declining immediately during the chase period. Experimentsusing responses of iNKT cells to analyze the kinetics of cell-
surface appearance gave analogous results (Figure S5). Thus,
although our findings did not provide evidence for presentation
by different APC types as a major factor accounting for the
altered cytokine responses to different analogs of aGalCer,
they revealed a consistent tendency for glycolipids that induced
Th2 cell-type biased cytokine responses to be presented with
more rapid kinetics compared to aGalCer analogs that induced
mixed Th1 and Th2 cell-type cytokine responses.
Direct Imaging of CD1d Loading with aGalCer Analogs
To visualize the kinetics and sites of mCD1d loading by aGalCer
analogs in live cells, we analyzed intact JAWS II cells for surface
staining with mAb L363 after 1, 4, or 16 hr of incubation with
aGalCer-C26:0 or with either of two Th2 cell-type cytokine-
biasing analogs (aGalCer-C20:2 or -C10:0) (Figure 4A). Strong
staining of the plasmamembrane was seen after 16 hr of incuba-
tion in all cases. However, only aGalCer-C20:2 or -C10:0 showed
L363 staining at earlier time points, consistent with the rapid
kinetics of loading observed by flow cytometry. To image earlier
steps in glycolipid loading, we permeabilized and fixed cells prior
to staining with L363 and with an antibody to the late endosomal
and lysosomal marker LAMP-1 (Figure 4A). After incubation for
1 hr with glycolipids, L363 staining was observed at the plasmaImmunity 30, 888–898, June 19, 2009 ª2009 Elsevier Inc. 891
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Loading of mCD1d with Different aGalCer
Analogs
(A) On the left, surface accumulation of CD1d-
aGalCer complexes was studied with JAWS II
cells harvested after incubation with the indicated
glycolipids for 1, 4, or 16 hr and then stained
without permeabilization with mAb L363 (red).
Cells were then fixed, stained with DAPI for nuclei
visualization (blue), and analyzed by confocal
microscopy. On the right, the intracellular forma-
tion and trafficking of CD1d-aGalCer complexes
were analyzed by treatment of JAWS II cells with
aGalCer analogs for 1, 4, and 16 hr followed by
fixation and permeabilization. The cells were
stained for CD1d-aGalCer complexes (L363,
red), late endosomes and lysosomes (anti-
LAMP-1, green), and nuclei (DAPI, blue). Results
are representative of three separate experiments.
The scale bar represents 10 mm.
(B) Murine iNKT cell hybridoma cells (DN3A4.1-2)
were stimulated with aGalCer analogs. As APCs
for these stimulations, we used A20 cells trans-
fected with wild-type CD1d (CD1d.WT) or
cytoplasmic-tail-deleted CD1d (CD1d.TD). Super-
natant concentrations of IL-2 release were deter-
mined after 12 hr. IL-2 production over a range of
concentrations is shown for aGalCer-C26:0 and
two analogs that produce a Th2 cell-type cytokine
bias (aGalCer-C20:2and -PGB1). Thebar graphon
the right shows relative potencies [(EC50 with
presentation by CD1d.WT)/(EC50 with presenta-
tion by CD1d.TD)] of each glycolipid presented
by CD1d.TD versus CD1d.WT.membrane for aGalCer-C20:2 and -C10:0, and no colocalization
with LAMP-1 was present. Colocalization with LAMP-1 was
observed for mCD1d complexes formed with these analogs
only at the latest time point studied (16 hr), suggesting that
they arrived at late endocytic compartments via recycling from
the plasma membrane. In contrast, L363 staining of cells pulsed
for 1 hr with aGalCer-26:0 was observed only in a punctate intra-
cellular distribution that was completely distinct from LAMP-1
staining, indicating that the initial association with mCD1d
occurred in an endocytic compartment separate from typical
late endosomes and lysosomes. At 4 hr, these complexes began
to colocalize with LAMP-1, and only at 16 hr could clear surface
staining be seen along with the persistent intracellular staining in
LAMP-1+ compartments (Figure 4A).
The lack of detectable intracellularmCD1d loading prior to cell-
surface mCD1d-aGalCer complex accumulation with Th2 cell-
type cytokine-biasing analogs suggested a reduced requirement
for endosomal loading as a general property of such glycolipids.
This was confirmedwith a functional assay to compare presenta-
tion of each analog by APCs expressing either wild-type mCD1d
(mCD1d.WT) or a cytoplasmic tail deletion mutant (mCD1d.TD)
deficient in endosomal trafficking and localization (Jayawar-
dena-Wolf et al., 2001) (Figure 4B). With A20 B lymphoma cells
expressing mCD1d.WT, aGalCer-C26:0 and -C24:0 were signif-
icantly more potent at activating iNKT cells compared to all Th2
cell-type cytokine-biasing analogs. In contrast, the opposite
was observed with A20 cells expressing mCD1d.TD. This inver-
sion of relative potencies was consistent with a requirement for892 Immunity 30, 888–898, June 19, 2009 ª2009 Elsevier Inc.endosomal loading of mCD1d by aGalCer-C26:0 and -C24:0
and with a general lack of this requirement for analogs that pref-
erentially induced Th2 cell-type cytokine responses.
Requirement for Lipid Transfer Factors
The efficient loading of CD1 molecules with lipids such as
aGalCer-C26:0 is known to involve cofactors that enhance the
transfer of lipids from micelles or membranes into the antigen-
binding groove of the CD1 protein. The best known of these
cofactors are resident intracellular lipid binding and transfer
proteins including those belonging to the saposin family, GM2
activator proteins, and Niemann-Pick type C1 and C2 proteins
(Zhou et al., 2004; Sagiv et al., 2006; Yuan et al., 2007; Schrantz
et al., 2007). Most of these are known to have detergent-like
activities that facilitate solubilization of lipids and their exchange
between hydrophobic binding sites. In an in vitro model for this
activity of endosomal lipid transfer proteins, we investigated
the impact of detergent (0.05% Triton X-100) on the loading of
aGalCer analogs onto purified mCD1d or hCD1d tetramers
(Figures 5A and 5B). With mCD1d, there was a clear enhancing
effect of Triton X-100 on the formation of tetramers that bound
to iNKT cell TCRs when aGalCer-C26:0 or -C24:0 were used
as ligands, whereas loading of all six Th2 cell-type cytokine-
biasing analogs was optimal in the absence of detergent
(Figure 5A). Largely similar findings were obtained with hCD1d
tetramers (OCH failed to form hCD1d tetramers with iNKT cell-
binding avidity under any conditions) (Figure 5B). Overall, this
consistent lack of detergent dependence for loading of CD1d
Immunity
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(A) Glycolipids were incubated for 24 hr at 37Cwithmurine CD1d proteins in the absence (top row) or presence (bottom row) of 0.05%Triton X-100. The resulting
complexes were assembled as tetramers and used for staining mouse iNKT hybridoma DN3A4.1-2. The dashed line histograms show background staining with
unloaded tetramers, and the bold histograms show staining with glycolipid loaded tetramers.
(B) The same analysis as in (A) except with human CD1d tetramers, which were also used for DN3A4.1-2 staining.
(C) Glycolipids at various concentrations were incubated with immobilized mCD1d protein for 2 hr in pH 7.0 or pH 5.0 buffers with no additives (medium) or in the
same buffers containing the indicated purified recombinant saposins (10 mg/ml) or Triton X-100 (0.05%). After washing, DN32.D3 iNKT hybridoma cells were
added and supernatant concentrations of IL-2 were determined after an additional 14 hr of incubation. All results shown (A, B, and C) were representative of
at least two independent experiments.by all Th2 cell-type cytokine-biasing analogs was a further
unifying feature of such compounds and pointed to differences
in aqueous solubility of aGalCer analogs as an important deter-
minant of their effects on iNKT cell activation.
To extend these observations to a more physiological model,
we tested the effects of purified recombinant saposin A, B, C,
and D proteins on loading of aGalCer analogs. In an in vitro
loading system with recombinant mCD1d and a functional
readout with iNKT cell hybridoma responses, we found that
loading of aGalCer-C26:0 was dependent either on the presence
of detergent (0.1% Triton X-100) or on the presence of a purified
saposin (Figure 5C). Saposin B was strongly active in this regard,
withminimal or no activity for saposins A, C, or D. This enhancing
effect of saposin B was observed at neutral pH and remained
strong and specific under acidic conditions approximating the
endosomal environment in which saposins normally function.In marked contrast, all four saposins showed only modest
enhancement of loading with aGalCer-C10:0 at neutral pH and
actually reduced mCD1d loading at acidic pH.
Lipid Raft Localization of aGalCer-CD1d Complexes
Recent studies highlight the localization of a fraction of CD1d
proteins to detergent insoluble plasma membrane microdo-
mains (i.e., lipid rafts) and suggest that this may have functional
relevance for iNKT cell activation (Lang et al., 2004; Park et al.,
2005; Peng et al., 2007). We assessed the potential involvement
of lipid rafts in controlling the cytokine bias of iNKT cell activation
by comparing the extent of raft colocalization of mCD1d com-
plexes forming in APCs pulsedwith aGalCer-C26:0 versus -C10:0
(Figure 6A). Consistent with the findings of Peng et al., a relatively
small fraction of total surfacemCD1d expressed by JAWS II cells
colocalized with lipid rafts, which were identified by the bindingImmunity 30, 888–898, June 19, 2009 ª2009 Elsevier Inc. 893
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Association of CD1d-aGalCer Complexes
(A) Top row shows steady state localization of total
cell-surface mCD1d on JAWS II cells (anti-mCD1d
mAb K253 (green), and cholera toxin B subunit
(CTxB) followed by clustering with anti-CTxB anti-
serum (red). Areas of overlap in the merged image
are shown in the black-and-white image on the
right (region of overlap). In the two lower rows,
JAWS II cells were incubated for 18 hr with the
indicated glycolipids and then stained with
CD1d-aGalCer complex-specific mAb L363
(green) and CTxB (red). Merged and region of
overlap images show marked colocalization of
mCD1d-aGalCer-C26:0 with GM1-enriched lipid
rafts, as opposed to minimal overlap for mCD1d-
aGalCer-C10:0 complexes. The scale bar repre-
sents 10 mm. Results shown for individual cells
were typical of >20 cells analyzed for each param-
eter with or without incubation with the indicated
glycolipids.
(B) Quantitation of colocalization shown in (A) for
multiple randomly selected individual cells. Pear-
son correlation coefficient for the distribution of
pixel densities for K253 or L363 fluorescence
compared to cholera toxin B-specific fluores-
cence are plotted for each individual cell analyzed.
Values for p were determined by one-way ANOVA.
(C) Flow cytometry assay for aGalCer-mCD1d
complex association with detergent-resistant me-
mbrane microdomains. JAWS II cells were incu-
bated with or without the indicated glycolipids for
18 hr and stained with mAbs K253 or L363. Base-
line fluorescence levels were recorded for 15 s,
after which Triton X-100 was added to 0.1%
(arrow) and recording was resumed for another
60 s. Each symbol indicates mean fluorescence
intensity (MFI) averaged over 1 s of recording. MFI
values were normalized to the mean baseline
levels for each sample during the initial 15 s of
recording. Results are representative of three
experiments.of cholera toxin B subunit (CTxB) to the GM1 gangliosides
enriched in these microdomains (Kenworthy et al., 2000). In
contrast, imaging of mAb L363 binding to cells that had been
incubated with aGalCer-C26:0 showed strong colocalization
with CTxB staining, indicating localization predominantly in lipid
rafts. This was not observed for L363 staining of cells incubated
with aGalCer-C10:0; this staining showed extremely limited
colocalization with CTxB staining indicating exclusion from
GM1-enriched lipid rafts (Figures 6A and 6B).
Another property of lipid rafts is their resistance to solubilization
by nonionic detergents due to their enrichment in cholesterol,
sphingomyelin, and saturated acyl chains (Pike, 2008). To assess
the localization ofaGalCer-mCD1dcomplexes in detergent insol-
uble microdomains, we used a flow-cytometry-based assay that
quantitates the resistance of lipid-raft-associated transmem-
brane proteins to extraction by low concentrations of Triton
X-100 (Gombos et al., 2004a; Peng et al., 2007). Using this
approach (Figure 6C), we observed that a substantial fraction
(70%) of total surface mCD1d (identified with mAb K253) could
be extracted from the cell surface within 90 s by 0.1% Triton894 Immunity 30, 888–898, June 19, 2009 ª2009 Elsevier Inc.X-100, consistent with a major nonraft localizing cohort of
mCD1d.Similarly, themajority of L363staining resulting frompre-
incubation of the cells with aGalCer-C10:0 was eliminated by
a brief exposure to 0.1% Triton X-100, indicating that mCD1d
complexes containing this glycolipid were mainly localized to
detergent soluble nonraft domains of the plasma membrane.
Complexes formed with aGalCer-C20:2 also showed significant
extraction by detergent in these experiments, although less
complete than foraGalCer-C10:0. In striking contrast, complexes
of mCD1d containing aGalCer-C26:0 were extremely resistant to
detergent extraction (90% remaining after 90 s).
These results strongly indicated that aGalCer analogs differ
profoundly with respect to presentation by lipid-raft-associated
or nonraft-associated mCD1d molecules, and such a difference
can be envisioned to have major effects on the strength and
quality of iNKT cell activation (Park et al., 2005). To assess func-
tional consequences of raft localization of CD1d-glycolipid
complexes, we analyzed the effects of methyl-b-cyclodextrin
(MbCD) treatment on the iNKT cell stimulatory capacity of
CD1d-glycolipid complexes in vitro and in vivo (Figure 7). MbCD
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brane Lipid Raft Association of Glycolipid-
Loaded CD1d Molecules
(A) C57BL/6 BMDCswere pulsed for 18 hr with the
indicated glycolipids, washed, and incubated for
15 min in medium alone (hatched bars) or medium
containing 10 mM MbCD (solid bars). Cells were
then fixed (1% paraformaldehyde) and used for
stimulating autologous splenocytes for 24 hr, after
which supernatant concentrations of IFN-g and
IL-4 were measured. Dotted lines indicate the
background levels of cytokines in cultures with
BMDC pulsed with vehicle only. Means and
standard deviations for triplicate cultures are
shown, and results are representative of three
experiments. **p < 0.01 (ANOVA, Bonferroni
post-test).
(B) Effect of MbCD on in vivo presentation of aGalCer analogs. Splenic DCs were pulsed ex vivo with the indicated glycolipids for 18 hr and then incubated for
15 min in medium without (, hatched bars) or with 10 mM MbCD (+, solid bars). After extensive washing, the cells were injected i.p. into naive C57BL/6 mice
(106 cells/mouse). Serum was assayed for IL-4 at 2 hr and for IFN-g at 24 hr postinjection. Data shown are means and standard deviations for pooled data from
two experiments that had three mice per group. **p < 0.01 (ANOVA, Bonferroni post-test); NS, not significant (p > 0.05).substantially disrupts lipid raft microdomain structures by
extracting cholesterol from the outer leaflet of the plasma
membrane and reduces the raft association of plasmamembrane
CD1dmolecules (Park et al., 2005). Treatment of DCs pulsedwith
aGalCer-C26:0withMbCDmarkedly reduced their ability to stim-
ulate IFN-g production by splenocytes and had no effect on stim-
ulation of IL-4. This effect was not observed for in vitro stimula-
tions with aGalCer-C20:2- or aGalCer-C10:0-pulsed DCs,
which were unaffected by MbCD (Figure 7A). A similar result
was obtained for in vivo iNKT cell stimulation after injection of
MbCD-treatedDCs (Figure 7B). These results implied that choles-
terol-rich plasmamembrane lipid raftswere highly relevant for the
mixedcytokine response toaGalCer-C26:0butweredispensable
for iNKT cell responses to Th2 cell-type cytokine-biasing
agonists, consistent with their lack of presentation by lipid-raft-
associated CD1d molecules.
DISCUSSION
Structurally modified forms of aGalCer have been explored in
recent years as a strategy for more selectively activating specific
functions of iNKT cells to exploit their therapeutic potential
(Miyamoto et al., 2001; Schmieg et al., 2003; Miyake and Yama-
mura, 2005; Yu et al., 2005; Forestier et al., 2007). The current
study addresses the fundamental mechanisms that cause
certain structural analogs of aGalCer to activate the strong, pref-
erential production of Th2 cell-type cytokines by iNKT cells that
is associated with anti-inflammatory or tolerizing effects. Our
studies extend other work centered mainly on the truncated
sphingosine analog known as OCH, which emphasized the
extremely low affinity or avidity of this ligand for iNKT cell
TCRs (Oki et al., 2004). The weak binding of OCH-loaded
CD1d molecules to the iNKT cell TCR, confirmed in the current
study, suggested that an affinity threshold model could account
for the Th2 cell-type cytokine bias and overall anti-inflammatory
effects that are observed after activation of iNKT cells with this
aGalCer variant (McCarthy et al., 2007).
However, our findings argue against an affinity threshold model
as the principle mechanism accounting for the properties of many
or most Th2 cell-type cytokine-biasing iNKT cell agonists. Asdemonstrated in an earlier study (Forestier et al., 2007) and
extendedhere, these analogs showeda remarkable range of avid-
ities for mouse or human iNKT cell TCRs. Structural studies of
CD1d-glycolipid complexes also suggest that altered functional
outcomes of iNKT cells to N-acyl variants are unlikely to be due
purely to direct effects on TCR affinity (Zajonc et al., 2005; Koch
et al., 2005; Borg et al., 2007). These studies reinforce the view
that alterations in the sphingoid base or acyl chain of aGalCer
are mostly hidden from the TCR contact surface by their posi-
tioning within the A’ and F’ pockets of the CD1d lipid-binding
groove. Although modeling suggests that a structural rearrange-
ment of the TCR contact surface may be a result of incomplete
filling of the A’ pocket by the truncated sphingoid base of OCH
(McCarthy et al., 2007), the high avidity of at least some Th2 cell-
type biasing N-acyl variants of aGalCer for iNKT cell TCRs argues
against sucheffects asa universal explanation for the altered cyto-
kine responses.Thus,mechanismsother thanor inaddition tovari-
ations in signaling based simply on TCR affinity must underlie the
alteredcytokine responsesstimulatedbycertainaGalCeranalogs.
An alternate mechanism supported by our data relates to how
these compounds become associated with CD1d in APCs. Our
findingsdid not strongly support thepreviously proposed hypoth-
esis that presentationbydifferent APC types accounts for qualita-
tive differences in iNKTcell responses (Bezbradica et al., 2005; Im
et al., 2006). Instead,what emerged strongly fromour studieswas
a consistent tendency for Th2 cell-type-biasing glycolipids to be
presented with rapid kinetics and without a requirement for intra-
cellular loading of CD1d, apparently as a result of their ability to
rapidly associatewith CD1dmolecules directly at the cell surface.
This was in marked contrast to aGalCer-C26:0, which underwent
intracellular loading and was presented more slowly. It is note-
worthy that a similar finding has been reported recently for
aGalCer-C20:2 in studies that used novel phage display-derived
antibodies with TCR-like specificity against the hCD1d/aGalCer
complexes (Denkberg et al., 2008), suggesting the potential rele-
vance of our observations to human iNKT cell responses.
The lack of a requirement for detergent or for a lipid transfer
protein (e.g., saposin B) as an accessory factor for glycolipid
loading was also consistently observed for Th2 cell-type-biasing
glycolipids, and we speculate that this was related directly toImmunity 30, 888–898, June 19, 2009 ª2009 Elsevier Inc. 895
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The chemical structures of aGalCer analogs with pronounced
Th2 cell-type cytokine-biasing effects are variable, but all of
these are characterized by substantial shortening of their
aliphatic chains or the inclusion of polar substitutions such as
double bonds or oxygen atoms. These modifications increase
the overall polarity and reduce the hydrophobicity of these glyco-
lipids relative to compounds giving mixed cytokine responses
like aGalCer-C26:0 and -C24:0, or the even more hydrophobic
Th1 cell-type cytokine-biasing C-glycoside variant of aGalCer-
C26:0 (Schmieg et al., 2003; Fujii et al., 2006).
Our demonstration that aGalCer analogs can differ markedly
with regard to the extent to which they are presented by lipid-
raft-associated CD1d molecules provides an attractive mecha-
nism to explain the stimulation of biased cytokine responses by
particular glycolipids. It is likely that the forced intracellular loading
of a compound such as aGalCer-C26:0 leads to the organized
transport of glycolipid-CD1d complexes into cholesterol-rich lipid
rafts, which also are known to facilitate recruitment into immuno-
logical synapses along with a variety of other molecules involved
in T cell activation (Gombos et al., 2004b). Conversely, direct
loading of CD1d molecules on the surface of the cell results in
exclusion from such lipid rafts and therefore promotes a very
different type of iNKT cell activation. Such lipid-raft-dependent
alternative activation, although novel for iNKT cells and CD1d-
dependent antigen recognition, has previously been described
in studies of MHC class II presentation that have remarkable
parallels with our observations on CD1d. For example, it has
been shown that a substantial fraction of plasmamembraneMHC
class II molecules are concentrated in cholesterol-rich lipid rafts
and tetraspanninmicrodomains (Poloso andRoche, 2004). Analo-
gous toourfindingswithCD1d-presentedglycolipids,peptideanti-
gens loaded onto MHC class II molecules in intracellular compart-
ments are presentedpreferentially in rafts and favor the stimulation
of Th1 cell-type responses by conventional CD4+ T cells. In
contrast, peptides loaded exogenously at the cell surface are pre-
sented mainly by molecules outside of rafts and show a tendency
to stimulate Th2 cell-type responses (Buatois et al., 2003).
Although our experiments used synthetic lipid agonists to show
how ligand structure may regulate the quality of iNKT cell
responses, the resultsmayprovide insight intohownatural endog-
enous and foreign lipid ligands are presented and sensed by the
CD1d-iNKT cell axis. Thus, the preferential loading of glycolipid
antigens with relatively short or polyunsaturated alkyl tails onto
cell-surface CD1d proteins may represent a constitutive process
of normal self -recognition that biases the immune system toward
toleranceor Th2 cell-type cytokine responses in the absenceof an
infectious agent. Interestingly, other recent data indicate that
glycolipids with this type of structure are not only more efficient
at loading directly onto surface CD1d but are also actively
excluded from forming stable complexes with endosomal CD1d
at low pH (A. Bendelac, personal communication). Such findings
are mirrored by our observation that recombinant saposins have
the ability to unload aGalCer-C10:0 from CD1d at pH 5.0, but
not at neutral pH. Taken together, these studies are evidence for
a finely tuned antigen-presenting system in which the sorting of
structurally divergent glycolipids onto different cohorts of CD1d
molecules is a keymechanism for regulating the balance between
tolerogenic and proinflammatory functions of iNKT cells.896 Immunity 30, 888–898, June 19, 2009 ª2009 Elsevier Inc.EXPERIMENTAL PROCEDURES
Mice, Cell Lines, and Reagents
Female C57BL/6 and BALB/c mice were purchased from the Jackson Labora-
tory and housed under specific pathogen-free conditions. All procedures were
approved by the Institutional Animal Use Committee. Murine iNKT hybridomas
DN3A4-1.2 (Va14Vb8.2) and DN3A4-1.4 (Va14Vb10) and A20 B lymphoma
cells transfected with wild-type or tail-deleted mouse CD1d proteins were
provided by M. Kronenberg (La Jolla Institute for Allergy and Immunology,
San Diego, CA, USA). Murine iNKT hybridomas N38.2H4 (Va14Vb7) and
DN32.D3 (Va14Vb8.2) were provided by K. Hayakawa (Fox Chase Cancer
Center, Philadelphia, PA, USA) and A. Bendelac (University of Chicago),
respectively. The C57BL/6.Trp53/-derived dendritic cell line JAWS II was
from the American Type Culture Collection. Murine cells were cultured in
RPMI-1640 with 10% fetal calf serum, 100 mM HEPES, and 50 mM 2-mercap-
toethanol (complete medium). Human iNKT cell clones and monocyte-derived
DCs were produced and cultivated as described (Exley et al., 1997). Mono-
clonal antibodies specific for mouse CD33 (clone 145-2C11, APC-conjugated),
NK1.1 (PK136, APC), CD11c (HL3, APC), and F4/80 (BM8, FITC) were
purchased from BD Biosciences. Anti-mouse CD19 (clone 6D5, SPRD) was
purchased from Southern Biotech. Monoclonal antibodies to human CD3
(OKT3, FITC) and to human iNKT invariant TCRa chain CDR3 region (6B11,
PE) were from BD Biosciences. Anti-LAMP-1 monoclonal antibody (clone
1D4B, Alexa Fluor 488) was from Santa Cruz Biotechnology. The mCD1d-
aGalCer complex-specific mAb L363 and mCD1d-specific mAb K253 were
produced in our laboratory (Yu et al., 2007).Monoclonal antibody pairs specific
for human and mouse cytokines were used in capture ELISAs as previously
described (Im et al., 2006; Forestier et al., 2007). Glycolipids used in this study
were synthesized and solubilized for in vivo injection or addition to cell culture
media as described (Ndonye et al., 2005; Yu et al., 2005; Forestier et al., 2007).
In Vitro and In Vivo Activation of iNKT Cells
For in vitro stimulation, murine iNKT hybridomas at 5 3 104 cells/well in 96-well
plateswerestimulatedwithanequal numberofeither JAWSII cellsor transfected
A20 cells in complete medium with glycolipids for 12 hr at 37C, and levels of
murine IL-2 secretion were determined. For some experiments, APCs were pre-
incubatedwith glycolipids for 12 hr or fixedwith paraformaldehyde (1% for 2min
at RT) prior to the addition of iNKT cell hybridomas. For in vitro stimulation of
murine splenic iNKT cells, splenocytes from BALB/c or C57BL/6 mice were
plated at 53 105 cells per well in complete medium in 96-well plates and stimu-
latedwith glycolipids for 48hr at 37C.Subsequently the levels of IL-4, IL-13, and
IFN-g in culture supernatants were quantified by capture ELISA. For assayswith
methyl-b-cyclodextrin (MbCD) treatment ofAPCs,weprepared splenicDCswith
aCD11c+ cell isolation kit fromMiltenyi Biotech frommice that hadbeen injected
s.c. 14 days previously with 105 Flt3-ligand-secreting B16 melanoma cells to
increase the yield (Mach et al., 2000). Purified CD11c+ cells were cultured in
complete medium for 18 hr with glycolipids (100 nM) as indicated, washed,
and incubated at 37C for 15 min in medium with or without 10 mM MbCD
(Sigma-Aldrich) and subsequently fixed (1% paraformaldehyde) and cultured
in 96-well plates at 23 105 cells/well with autologous splenocytes (43 105 cells
perwell). Supernatantswere harvested 24hr later formeasurement of cytokines.
In vivo activation of iNKT cells by i.p. glycolipid injection (4 nmoles) of female
C57BL/6 mice and measurement of serum cytokines was done as previously
described (Forestier et al., 2007). For determination of MbCD effects on in vivo
presentation, CD11c+ purified splenic DCs from C57BL/6 mice injected s.c.
14 days previously with 105 Flt3-ligand-secreting B16 melanoma cells were
cultured in complete medium with 100 nM of glycolipids for 18 hr, washed, and
incubated for 15min inRPMI-1640with orwithout 10mMMbCD. After extensive
washing, the cells were injected i.p. into naive C57BL/6 mice (106 cells/mouse),
and blood was collected at 2 hr and 24 hr for analysis of serum cytokine levels.
CD1d Tetramer Assembly and Flow Cytometry
Recombinant CD1d proteins were produced and assembled into tetramers for
staining as previously described (Forestier et al., 2007). To obtain optimally
loaded tetramers for iNKT cell staining, we loaded mCD1d with aGalCer-
C26:0 and -C24:0 in the presence of 0.05% Triton X-100 (Sigma-Aldrich)
and loaded mCD1d with other glycolipids without Triton X-100. For loading
of hCD1d, 0.05% Triton X-100 was included with aGalCer-C26:0, -C24:0,
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surface staining of aGalCer/mCD1d complexes, murine splenocytes or
JAWS II cells were incubated with 250 nM glycolipids for various times and
then 0.2 mg/ml mAb L363 (Alexa Fluor 647 or biotin conjugated) was added
directly to the culture for an additional 30 min at RT. In some experiments,
additional fluorochrome-conjugated antibodies specific for leukocyte subpop-
ulations were added for the last 15 min of incubation. All samples were
analyzed with the FACSCalibur flow cytometer (BD Biosciences).
In Vitro CD1d Loading Assay
Recombinant murine CD1d proteins at 4 mg/ml in 50 ml PBSwere coated on the
surfaces of microtiter plate wells for 2 hr at 37C and then washed with PBS for
removal of unbound proteins. Subsequently, various concentrations of glyco-
lipids in 0.1 M sodium phosphate buffer (pH 7.0) or 0.1 M sodium citrate buffer
(pH 5.0) containing 150 mMNaCl were incubated with or without 0.05% Triton
X-100 or recombinant purified human saposins A, B, C, or D at 10 mg/ml for
another 2 hr at 37C. Saposins were produced and purified as described
(Yuan et al., 2007). After extensive washing with PBS and media, 5 3 104
murine iNKT hybridoma DN32.D3 cells were added in 200 ml of complete
medium and incubated at 37C for 14 hr. Supernatants were analyzed for
murine IL-2 by capture ELISA.
Confocal Microscopy and Lipid Raft Analysis
JAWS II cells were incubated at 37Cwith 100 nM glycolipids for various times
as indicated. For surface staining, live cells were harvested and washed exten-
sively with PBS, resuspended in PBS + 1% BSA + 0.1% NaN3, stained on ice
with 10 mg/ml Alexa Fluor 647-conjugated mAb L363 for 30 min, and lastly
washed extensively and fixed with 4% paraformaldehyde. Cells were washed
with PBS and settled onto poly-L-lysine-coated coverslips for 30 min and
mounted with ProLong Gold with DAPI mounting medium (Invitrogen). For
intracellular staining, JAWS II cells grown on glass coverslips were fixed in
4% paraformaldehyde, permeabilized with 0.05% Triton X-100 for 5 min,
and stained with 10 mg/ml Alexa Fluor 647-conjugated L363 and FITC-conju-
gated anti-LAMP-1. Coverslips were washed and mounted. Confocal images
were obtained with a Leica SP2 AOBS confocal microscope (Leica Microsys-
tems). For colocalization of aGalCer/mCD1d complexes with ganglioside
GM1-enriched plasma membrane lipid rafts, JAWS II cells were incubated for
18 hr at 37C in complete medium without or with 100 nM of glycolipids. Cells
were thenwashedwith PBS, resuspended in PBS+ 1%BSA+0.1%NaN3, and
stained on ice with the 10 mg/ml of Alexa Fluor 647-conjugated mAb L363 or
mAb K253 plus cholera toxin B subunit (Invitrogen) for 30 min. After washing
once with PBS, cells were incubated with Texas Red-conjugated rabbit anti-
cholera toxin B, fixed, and mounted for confocal microscopy. We performed
quantitative analysis of colocalization by selecting 20–25 random cells in
each group and determining a Pearson correlation coefficient for the distribu-
tion of pixel densities for K253 or L363 fluorescence compared to cholera toxin
B-specific fluorescence. Assessment of mCD1d or aGalCer/mCD1d complex
association with detergent resistant membrane microdomains by flow cytom-
etry was carried out with accordance to a published protocol (Gombos et al.,
2004a). JAWS II cells were incubated in complete mediumwith or without indi-
cated glycolipids for 18 hr, harvested, washed, and resuspended in PBS with
1% FCS. After staining with Alexa Flour 647 conjugates of mAbs K253 or
L363, cells were resuspended at 106/ml in PBS with 1% FCS and analyzed
for fluorescence with the kinetic mode for acquisition with time as a variable
with Cell Quest software and the FACSCalibur (BD Biosciences). After
recording baseline fluorescence for 15 s, Triton X-100 was added to a final
concentration of 0.1%with brief (1 s) vortexing tomix, and acquisition of fluo-
rescence level in kinetic mode was continued for another 60 s.
SUPPLEMENTAL DATA
Supplemental Data include five figures and can be found with this article online
at http://www.cell.com/immunity/supplemental/S1074-7613(09)00238-6.
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